Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.

Further Reading

Study: One in five young adults in India has hypertension

Study: One in five young adults in India has hypertension

Gut protein mutations protect against spikes in blood glucose levels

Gut protein mutations protect against spikes in blood glucose levels

Non-coding genetic variant plays key role in endothelial function and disease incidence

Non-coding genetic variant plays key role in endothelial function and disease incidence

Mylan and Biocon launch new insulin glargine biosimilar in the UK

Mylan and Biocon launch new insulin glargine biosimilar in the UK

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

High-impact clinical trial results could affect kidney-related medical care

High-impact clinical trial results could affect kidney-related medical care

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Eisai enters into agreement with Eurofarma for development and sales of lorcaserin in 17 countries

Length of hospital stay and readmission likelihood increases by 2.9% in rural areas, review finds

Length of hospital stay and readmission likelihood increases by 2.9% in rural areas, review finds

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

Study investigates effects of glucose-lowering drug in preventing damage to the kidneys

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Study aims to investigate antimicrobial resistance of uropathogenic E. coli from elderly patients

Study aims to investigate antimicrobial resistance of uropathogenic E. coli from elderly patients

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

CHMP issues positive opinion supporting use of Trelegy Ellipta in broader group of COPD patients

New study reveals mechanisms that lead to cognitive decline in Type 2 diabetes

New study reveals mechanisms that lead to cognitive decline in Type 2 diabetes

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

Study aims to investigate risk factors for PPCs in surgical patients with gastric cancer

EC approves update of INVOKANA and VOKANAMET labeling to include changes to indication statement

EC approves update of INVOKANA and VOKANAMET labeling to include changes to indication statement